Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease

References

• Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn’s disease. Dig Dis 1975;20:721–6.
   Google Scholar
• Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn’s disaese with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980;302:981–7.
   PubMed Web of Science ®Google Scholar
• Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut 1995;37:674–8.
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis. Ann Intern Med 1995;123:132–42.
   PubMed Web of Science ®Google Scholar
• Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on a therapeutic trial. Br Med J 1974;4:627–30.
   PubMed Web of Science ®Google Scholar
• Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in ulcerative colitis. Br Med J 1982;284:1291–2.
   PubMed Web of Science ®Google Scholar
• Hawthorne AB, Logan RFA, Hawkey CJ, Foster PN, Axon ATR, Swarbrick ET, et al. Randomized controlled trial of azathioprine withdrawal in ulcerative colitis. Br Med J 1992;305:20–2.
   PubMed Web of Science ®Google Scholar
• Lennard L, Lilleyman JS. Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase polymorphism. Ther Drug Monit 1996; 18: 328–34.
   PubMed Web of Science ®Google Scholar
• Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xantine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 1991;50:663–72.
   PubMed Web of Science ®Google Scholar
• Zimm S, Collins JM, Riccardi R, O’Neill D, Narang PK, Chabner B, et al. Variable bioavailability of oral mercaptopurine. Is maintenance chemotherapy in acute lymphoblastic leukaemia being optimally delivered? N Engl J Med 1983;308:1005–9.
   Google Scholar
• Van Os EC, Zins BJ, Sandborn WJ, Mays DC, Tremaine WJ, Mahoney DW, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996;39:63–8.
   PubMed Web of Science ®Google Scholar
• Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148–59.
   PubMedGoogle Scholar
• Schutz E, von Ahsen N, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: three-color multiplexing, ‘two-color/shared’ anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem. 2000;46:1728–37.
   PubMed Web of Science ®Google Scholar
• Hon YY, Fessing MY, Pui CH, Relling MV, Krynetski EY, Evans WE. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet. 1999;8:371–6.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651–62.
   PubMed Web of Science ®Google Scholar
• Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24 Suppl 170):2–616–19.
   Google Scholar
• Best WR, Becktel JM, Singleton JW. Development of a Crohn’s Disease Activity Index: national cooperative Crohn’s disease study. Gastroenterology 1976;70:439–44.
   Google Scholar
• Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI). Gastroenterology 1979;77:843–6.
   Google Scholar
• Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992;87:971–6.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease. Gastroenterology 1999;117:527–35.
   PubMed Web of Science ®Google Scholar
• Bruunshuus I, Schmiegelow K. Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. Scand J Clin Lab Invest 1989;49:779–84.
   PubMed Web of Science ®Google Scholar
• Erdmann GR, France LA, Bostrom BC, Canafax DM. A reversed phase high performance liquid chromatography approach in determining total red blood cell concentrations of 6-thioguanine, 6-mercaptopurine, methylthioguanine, and methylmercaptopurine in a patient receiving thiopurine therapy. Biomed Chromatogr 1990;4:47–51.
   PubMed Web of Science ®Google Scholar
• Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323–33.
   Google Scholar
• Otterness D, Szumlanski C, Lennard L, Klemetsdal B, Aarbakke J, Park-Hah JO, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymophisms. Clin Pharmacol Ther 1997;62:60–73.
   Google Scholar
• Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996;91:423–33.
   PubMed Web of Science ®Google Scholar
• Cuffari C, Théorêit Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity. Gut 1996;39:401–6.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêit Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118: 705–13.
   Google Scholar
• Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001;48: 642–6.
   Google Scholar
• Achkar JP, Stevens T, Brzezinski A, Seidner D, Lashner B. 6-Thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy [abstract]. Am J Gastroenterol 2000;95:A272.
   Google Scholar
• Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukaemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998;42: 266–72.
   Google Scholar
• Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904–15.
   PubMed Web of Science ®Google Scholar
• Lennard L, Welch J, Lilleyman JS. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites. Br J Clin Pharmacol 1996;42:525–7.
   Google Scholar
• Szumlanski CL, Weinshilboum RM. Sulfasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456–9.
   PubMed Web of Science ®Google Scholar
• Lowry PW, Franklin CL, Weaver AL, Szumlanski CL, Mays DC, Loftus EV, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001;49:656–64.
   PubMedGoogle Scholar
• Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM. Thiopurine pharmacogenetics in leukemia: correlation of erytrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther 1987;41: 18–25.
   PubMed Web of Science ®Google Scholar
• Kaskas B, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F, et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine. Gut 2003;52:140–2.
   PubMed Web of Science ®Google Scholar
• Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn’s disease. Am J Gastroenterol 1994;89:362–6.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Mandel F, Daum F, the 6-MP Collaborative Group. Relationship of leukopenia to 6-MP induced remission of Crohn’s disease [abstract]. J Pediatr Gastroenterol Nutr 1998;27:A8.
   Google Scholar
• Nygaard U, Toft N, Schmiegelow K. Methylated metabolites of 6-mercaptopurine are associated with hepatotoxicity. Clin Pharmacol Ther 2004;75: 274–81.
   Google Scholar
• Schmiegelow K, Björk O, Glomstein A, Gustafsson G, Keiding N, Kristinsson J, et al. Intensification of mercaptopurine/ methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukaemia. J Clin Oncol 2003;21:1332–9.
   PubMedGoogle Scholar